News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
735,360 Results
Type
Article (64835)
Company Profile (467)
Press Release (670038)
Multimedia
Podcasts (178)
Webinars (24)
Section
Business (184441)
Career Advice (3303)
Deals (33498)
Drug Delivery (141)
Drug Development (84684)
Employer Resources (184)
FDA (16517)
Job Trends (15024)
News (326875)
Policy (32462)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2964)
Academic (1)
Accelerated approval (40)
Adcomms (37)
Allergies (161)
Alliances (47936)
ALS (194)
Alzheimer's disease (1827)
Antibody-drug conjugate (ADC) (376)
Approvals (16728)
Artificial intelligence (614)
Autoimmune disease (210)
Automation (45)
Bankruptcy (324)
Best Places to Work (12022)
BIOSECURE Act (23)
Biosimilars (205)
Biotechnology (325)
Bladder cancer (176)
Brain cancer (70)
Breast cancer (699)
Cancer (5346)
Cardiovascular disease (471)
Career advice (2819)
Career pathing (43)
CAR-T (320)
CDC (62)
Celiac Disease (2)
Cell therapy (875)
Cervical cancer (41)
Clinical research (72003)
Collaboration (1940)
Company closure (6)
Compensation (1195)
Complete response letters (86)
COVID-19 (2909)
CRISPR (109)
C-suite (940)
Cystic fibrosis (157)
Data (6784)
Decentralized trials (2)
Denatured (53)
Depression (168)
Diabetes (540)
Diagnostics (6871)
Digital health (52)
Diversity (12)
Diversity, equity & inclusion (47)
Drug discovery (303)
Drug pricing (216)
Drug shortages (33)
Duchenne muscular dystrophy (271)
Earnings (74481)
Editorial (68)
Employer branding (23)
Employer resources (165)
Events (130701)
Executive appointments (1014)
FDA (19874)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (26)
Funding (1623)
Gene editing (232)
Generative AI (57)
Gene therapy (727)
GLP-1 (1104)
Government (5153)
Grass and pollen (8)
Guidances (385)
Healthcare (20078)
HIV (75)
Huntington's disease (56)
IgA nephropathy (92)
Immunology and inflammation (307)
Immuno-oncology (79)
Indications (138)
Infectious disease (3218)
Inflammatory bowel disease (217)
Inflation Reduction Act (17)
Influenza (126)
Intellectual property (267)
Interviews (634)
IPO (16444)
IRA (58)
Job creations (3376)
Job search strategy (2277)
JPM (72)
Kidney cancer (18)
Labor market (87)
Layoffs (604)
Leadership (43)
Legal (7261)
Liver cancer (101)
Longevity (20)
Lung cancer (709)
Lymphoma (398)
Machine learning (48)
Management (63)
Manufacturing (892)
MASH (184)
Medical device (14010)
Medtech (14077)
Mergers & acquisitions (18224)
Metabolic disorders (1452)
mRNA (197)
Multiple sclerosis (178)
NASH (21)
Neurodegenerative disease (389)
Neuropsychiatric disorders (109)
Neuroscience (3253)
Neurotech (1)
NextGen: Class of 2026 (7145)
Non-profit (4941)
Now hiring (53)
Obesity (702)
Opinion (339)
Ovarian cancer (176)
Pain (234)
Pancreatic cancer (249)
Parkinson's disease (320)
Partnered (36)
Patents (538)
Patient recruitment (567)
Peanut (63)
People (55788)
Pharmaceutical (83)
Pharmacy benefit managers (30)
Phase 1 (22569)
Phase 2 (31670)
Phase 3 (23526)
Pipeline (6291)
Policy (354)
Postmarket research (2732)
Preclinical (9910)
Press Release (70)
Prostate cancer (273)
Psychedelics (61)
Radiopharmaceuticals (317)
Rare diseases (1032)
Real estate (5980)
Recruiting (78)
Regulatory (25010)
Reports (46)
Research institute (2692)
Resumes & cover letters (535)
Rett syndrome (31)
RNA editing (21)
RSV (88)
Schizophrenia (164)
Series A (275)
Series B (204)
Service/supplier (11)
Sickle cell disease (110)
Special edition (29)
Spinal muscular atrophy (180)
Sponsored (47)
Startups (3608)
State (2)
Stomach cancer (21)
Supply chain (112)
Tariffs (89)
The Weekly (122)
Vaccines (1122)
Venture capital (103)
Weight loss (472)
Women's health (99)
Worklife (23)
Date
Today (168)
Last 7 days (721)
Last 30 days (3188)
Last 365 days (31431)
2026 (6123)
2025 (31671)
2024 (36624)
2023 (41342)
2022 (52532)
2021 (57121)
2020 (55556)
2019 (48919)
2018 (36941)
2017 (33362)
2016 (33325)
2015 (38606)
2014 (31270)
2013 (26699)
2012 (28500)
2011 (28631)
2010 (26839)
Location
Africa (972)
Alabama (92)
Alaska (7)
Arizona (279)
Arkansas (15)
Asia (42667)
Australia (7516)
California (11940)
Canada (3417)
China (1219)
Colorado (499)
Connecticut (512)
Delaware (347)
Europe (99193)
Florida (1774)
Georgia (382)
Hawaii (3)
Idaho (60)
Illinois (966)
India (77)
Indiana (531)
Iowa (22)
Japan (463)
Kansas (130)
Kentucky (44)
Louisiana (36)
Maine (83)
Maryland (1466)
Massachusetts (8849)
Michigan (341)
Minnesota (663)
Mississippi (6)
Missouri (142)
Montana (35)
Nebraska (27)
Nevada (128)
New Hampshire (77)
New Jersey (3201)
New Mexico (33)
New York (3202)
North Carolina (1582)
North Dakota (9)
Northern California (5834)
Ohio (365)
Oklahoma (22)
Oregon (43)
Pennsylvania (2390)
Puerto Rico (22)
Rhode Island (48)
South America (1295)
South Carolina (65)
Southern California (4671)
Tennessee (181)
Texas (1847)
United States (42741)
Utah (341)
Vermont (1)
Virginia (287)
Washington D.C. (80)
Washington State (991)
West Virginia (4)
Wisconsin (117)
Wyoming (2)
735,360 Results for "ivy brain tumor center at the barrow neurological institute".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Ivy Brain Tumor Center announces Phase 0/2 clinical readout of niraparib indicating significant improvement in overall survival of newly diagnosed glioblastoma patients
The Ivy Brain Tumor Center at Barrow Neurological Institute announced a clinical readout of a Phase 0/2 ‘trigger’ clinical trial of niraparib in patients with newly diagnosed MGMT-unmethylated glioblastoma.
May 23, 2024
·
4 min read
Business
Ivy Brain Tumor Center Builds On Innovative Clinical Trial Program by Appointing New Chief Medical OfficerLeading Neuro-Oncologist Yoshie Umemura, MD, Joins Barrow Neurological Institute
The Ivy Brain Tumor Center and Barrow Neurological Institute are pleased to announce the addition of Yoshie Umemura, MD, as the new Chief Medical Officer of the Ivy Brain Tumor Center and Chief of Neuro-Oncology and the William and Joan Shapiro Chair of Neuro-Oncology at Barrow Neurological Institute.
May 23, 2023
·
4 min read
Press Releases
Shared origins illuminate potential dependency across brain tumor types
March 5, 2026
·
6 min read
Drug Development
Ivy Brain Tumor Center Announces Promising Data for Niraparib in Phase 0/2 Glioblastoma Clinical Trial
The Ivy Brain Tumor Center at Barrow Neurological Institute announces promising results from a Phase 0/2 trial of niraparib in patients with newly diagnosed glioblastoma with unmethylated MGMT.
November 17, 2023
·
4 min read
Drug Development
Ivy Brain Tumor Center Announces Results of Phase 0/1 Study in Recurrent Glioblastoma Patients at the European Society for Medical Oncology (ESMO) 2023 Congress
The Ivy Brain Tumor Center at Barrow Neurological Institute announced initial results from a Phase 0/1 clinical trial of the Ataxia telangiectasia mutated kinase inhibitor AZD1390 in recurrent glioblastoma in combination with radiation therapy.
October 18, 2023
·
3 min read
Press Releases
The Mark Foundation and The Sontag Foundation Lead Coalition to Propel Novel Brain Tumor Therapy Research with $4 Million in New Grants
February 11, 2026
·
4 min read
Mergers & acquisitions
Servier Adds to Childhood Brain Tumor Portfolio With $2.5B Day One Buy
Servier will pick up Ojemda, which received FDA approval in 2024 to treat pediatric glioma. The drug clocked sales of $155 million for Day One Biopharmaceuticals in 2025.
March 6, 2026
·
1 min read
·
Annalee Armstrong
Press Releases
Salma Health Launches Integrated Brain Health Center of Excellence, Ushering in a New Era for Comprehensive Brain Care, Technology, and Research
February 26, 2026
·
7 min read
Ivy Brain Tumor Center Opens Novel Clinical Trial to Test Direct-to-Tumor Drug Delivery MethodInnovative technique aims to bypass the most difficult barrier in brain cancer treatment
In an effort to discover new treatments for brain tumors, such as glioblastoma, the Ivy Brain Tumor Center at Barrow Neurological Institute, announced the initiation of a ground-breaking Phase 0 clinical trial that tests a new experimental drug delivery method called superselective intra-arterial infusion, or SSIAI.
July 18, 2023
·
4 min read
Press Releases
Prospective Multicenter Registry Study Reports High Local Tumor Control Following Resection with GammaTile® in Newly Diagnosed Brain Metastases
February 26, 2026
·
4 min read
1 of 73,536
Next
